Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02844582 |
Recruitment Status :
Terminated
(Poor accrual of subjects onto study)
First Posted : July 26, 2016
Results First Posted : January 25, 2021
Last Update Posted : January 25, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hormone-Resistant Prostate Cancer Stage IV Prostate Adenocarcinoma | Drug: Cabazitaxel Drug: Prednisone | Phase 2 |
PRIMARY OBJECTIVES:
I. To test whether men with a poor initial response to androgen deprivation therapy (ADT) have a better front line therapeutic response to cabazitaxel as compared to historical controls of frontline metastatic castrate resistant prostate cancer (CRPC) therapy with abiraterone or enzalutamide.
SECONDARY OBJECTIVES:
I. To determine the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 response rate, progression free survival (PFS) by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria, and overall survival (OS).
II. To evaluate safety and toxicity profile of cabazitaxel in patients with CRPC.
TERTIARY OBJECTIVES:
I. To collect serum and tumor tissue samples for molecular markers or signature predictive of cabazitaxel benefit (to include status of androgen receptor [AR] pathway, androgen biosynthetic pathway genes, adenosine triphosphate [ATP]-binding cassette sub-family B member 1 [ABCBI], multidrug resistance-associated protein 1 [MRP1], and other mediators of taxane resistance).
OUTLINE:
Patients receive cabazitaxel intravenously (IV) over 1 hour on day 1 and prednisone orally (PO) twice daily (BID) on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers |
Actual Study Start Date : | December 20, 2017 |
Actual Primary Completion Date : | June 4, 2019 |
Actual Study Completion Date : | June 4, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (cabazitaxel, prednisone)
Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: Cabazitaxel
Given IV
Other Names:
Drug: Prednisone Given PO
Other Names:
|
- PSA Response Rate, Defined as >= 50% Decline in PSA From Baseline Maintained for at Least 3 Weeks and Measured by the Same Laboratory, and Without Evidence of Other Disease Progression Documented at Time of Confirmatory Values [ Time Frame: Up to 18 months. ]The response rate will be compared to a historical response rate of 20% using the exact binomial test for a single proportion. Confidence intervals for the response rate will be calculated using Wilson's method.
- Incidence of Adverse Events, Serious Adverse Events, and Discontinuations, Described and Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 [ Time Frame: Up to 28 days after discontinuation of study drug ]Incidence of adverse events, serious adverse events, and discontinuations, described and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
- Overall Survival (OS) Defined as the Time Interval From the Date of Enrollment to the Date of Death Due to Any Cause. [ Time Frame: Up to 18 months. ]Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method.
- Progression-free Survival (PFS) Defined as the Time Interval Between the Date of Enrollment and the Date of the First Documentation by the Prostate Cancer Working Group 2 (PCWG2) Criteria. [ Time Frame: Approximately 5 months. ]Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method.
- Response Evaluation Criteria in Solid Tumors (RECIST) Response Defined as Radiographic Disease Progression [ Time Frame: Approximately 5 months. ]Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed prostate adenocarcinoma
- Metastatic disease
- Able and willing to provide informed consent and to comply with the study procedures
- Castration resistant disease defined as evidence of radiological and/or prostate specific antigen (PSA) progression despite castrate levels of testosterone (serum testosterone < 50 ng/dL [1.7 nmol/L]); for PSA progression, there must be at least 2 sequential rises at a minimum of 1-week intervals; the first PSA value must be >= 4 (Prostate Cancer Working Group 2 [PCWG2] criteria)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- At least 21 days have passed since completing radiotherapy (exception for radiotherapy: at least 7 days since completing a single fraction of =< 800 cGy to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit) at the time of registration
- At least 21 days have passed since receiving any investigational agent at the time of registration
- At least 21 days have passed since major surgery
- Neuropathy =< grade 1 at the time of registration
- Has recovered from all therapy-related toxicity to =< grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy) at the time of registration
-
Poor prognosis disease as defined by any of the following:
- PSA nadir >=4.0, or
- Gleason score 8-10, or
- Time from ADT initiation to CRPC of =< 16 months
- Hemoglobin >= 90 g/L
- Neutrophils >= 1.5 x 10^9 /L
- Platelets >= 100 x 10^9/L
- Aspartate aminotransferase (AST) < 1.5 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT) < 1.5 x ULN
- Bilirubin =< 1.0 x ULN (exceptions for Gilbert's syndrome)
- Creatinine =< 1.5 x ULN
Exclusion Criteria:
- Prior therapy with cabazitaxel or to other drugs formulated with polysorbate 80
- Prior taxanes for CRPC
- Prior enzalutamide, abiraterone or ketoconazole
- Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with administration of cabazitaxel, study participation, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study
- Histologic evidence of small cell/neuroendocrine prostate cancer
- Patients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose; the definition of "effective method of contraception" will be based on the investigator's judgment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02844582
United States, California | |
University of California Davis Comprehensive Cancer Center | |
Sacramento, California, United States, 95817 |
Principal Investigator: | Christopher Evans | University of California, Davis |
Documents provided by University of California, Davis:
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT02844582 |
Other Study ID Numbers: |
868922 UCDCC#261 ( Registry Identifier: UC Davis IRB ) UCDCC#261 ( Other Identifier: University of California Davis Comprehensive Cancer Center ) NCI-2016-00961 ( Other Identifier: CTRP (Clinical Trial Reporting Program) ) |
First Posted: | July 26, 2016 Key Record Dates |
Results First Posted: | January 25, 2021 |
Last Update Posted: | January 25, 2021 |
Last Verified: | January 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Prednisone Cortisone |
Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents |